RATIONALE: The aromatase inhibitor anastrozole blocks the conversion of androgens to estrogen and blunts pulmonary hypertension in animals, but its efficacy in treating patients with pulmonary arterial hypertension (PAH) is unknown. OBJECTIVES: We aimed to determine the safety and efficacy of anastrozole in PAH. METHODS: We performed a randomized, double-blind, placebo-controlled trial of anastrozole in patients with PAH who received background therapy at two centers. MEASUREMENTS AND MAIN RESULTS: A total of 18 patients with PAH were randomized to anastrozole 1 mg or matching placebo in a 2:1 ratio. The two co-primary outcomes were percent change from baseline in 17β-estradiol levels (E2) and tricuspid annular plane systolic excursion (TAPSE) at 3 months. Anastrozole significantly reduced E2 levels compared with placebo (percent change: -40%; interquartile range [IQR], -61 to -26% vs. -4%; IQR, -14 to +4%; P = 0.003), but there was no difference in TAPSE. Anastrozole significantly increased the 6-minute-walk distance (median change = +26 m) compared with placebo (median change = -12 m) (median percent change: anastrozole group, 8%; IQR, 2 to 17% vs. placebo -2%; IQR, -7 to +1%; P = 0.042). Anastrozole had no effect on circulating biomarkers, functional class, or health-related quality of life. There was no difference in adverse events. CONCLUSIONS:Anastrozole significantly reduced E2 levels in patients with PAH but had no effect on TAPSE. Anastrozole was safe, well tolerated, and improved 6-minute-walk distance in this small "proof-of-principle" study. Larger and longer phase II clinical trials of anastrozole may be warranted in patients with PAH. Clinical trial registered with www.clinicaltrials.gov (NCT 1545336).
RCT Entities:
RATIONALE: The aromatase inhibitor anastrozole blocks the conversion of androgens to estrogen and blunts pulmonary hypertension in animals, but its efficacy in treating patients with pulmonary arterial hypertension (PAH) is unknown. OBJECTIVES: We aimed to determine the safety and efficacy of anastrozole in PAH. METHODS: We performed a randomized, double-blind, placebo-controlled trial of anastrozole in patients with PAH who received background therapy at two centers. MEASUREMENTS AND MAIN RESULTS: A total of 18 patients with PAH were randomized to anastrozole 1 mg or matching placebo in a 2:1 ratio. The two co-primary outcomes were percent change from baseline in 17β-estradiol levels (E2) and tricuspid annular plane systolic excursion (TAPSE) at 3 months. Anastrozole significantly reduced E2 levels compared with placebo (percent change: -40%; interquartile range [IQR], -61 to -26% vs. -4%; IQR, -14 to +4%; P = 0.003), but there was no difference in TAPSE. Anastrozole significantly increased the 6-minute-walk distance (median change = +26 m) compared with placebo (median change = -12 m) (median percent change: anastrozole group, 8%; IQR, 2 to 17% vs. placebo -2%; IQR, -7 to +1%; P = 0.042). Anastrozole had no effect on circulating biomarkers, functional class, or health-related quality of life. There was no difference in adverse events. CONCLUSIONS:Anastrozole significantly reduced E2 levels in patients with PAH but had no effect on TAPSE. Anastrozole was safe, well tolerated, and improved 6-minute-walk distance in this small "proof-of-principle" study. Larger and longer phase II clinical trials of anastrozole may be warranted in patients with PAH. Clinical trial registered with www.clinicaltrials.gov (NCT 1545336).
Entities:
Keywords:
anastrozole; clinical trial; pulmonary hypertension; sex hormones
Authors: Kirsty M Mair; Audrey F Wright; Nicholas Duggan; David J Rowlands; Martin J Hussey; Sonia Roberts; Josephine Fullerton; Margaret Nilsen; Lynn Loughlin; Matthew Thomas; Margaret R MacLean Journal: Am J Respir Crit Care Med Date: 2014-08-15 Impact factor: 21.405
Authors: E D Austin; J D Cogan; J D West; L K Hedges; R Hamid; E P Dawson; L A Wheeler; F F Parl; J E Loyd; J A Phillips Journal: Eur Respir J Date: 2009-04-08 Impact factor: 16.671
Authors: Tim Lahm; Ketan M Patel; Paul R Crisostomo; Troy A Markel; Meijing Wang; Christine Herring; Daniel R Meldrum Journal: Am J Physiol Endocrinol Metab Date: 2007-06-26 Impact factor: 4.310
Authors: Corey E Ventetuolo; Nandita Mitra; Fei Wan; Ani Manichaikul; R Graham Barr; Craig Johnson; David A Bluemke; Joao A C Lima; Hari Tandri; Pamela Ouyang; Steven M Kawut Journal: Eur Respir J Date: 2015-12-02 Impact factor: 16.671
Authors: Yi Ling; Martin K Johnson; David G Kiely; Robin Condliffe; Charlie A Elliot; J Simon R Gibbs; Luke S Howard; Joanna Pepke-Zaba; Karen K K Sheares; Paul A Corris; Andrew J Fisher; James L Lordan; Sean Gaine; J Gerry Coghlan; S John Wort; Michael A Gatzoulis; Andrew J Peacock Journal: Am J Respir Crit Care Med Date: 2012-07-12 Impact factor: 21.405
Authors: Yvonne Dempsie; Margaret Nilsen; Kevin White; Kirsty M Mair; Lynn Loughlin; Noona Ambartsumian; Marlene Rabinovitch; Margaret R Maclean Journal: Respir Res Date: 2011-12-20
Authors: Kevin White; Anne Katrine Johansen; Margaret Nilsen; Loredana Ciuclan; Emma Wallace; Leigh Paton; Annabel Campbell; Ian Morecroft; Lynn Loughlin; John D McClure; Matthew Thomas; Kirsty M Mair; Margaret R MacLean Journal: Circulation Date: 2012-08-02 Impact factor: 29.690
Authors: Anna R Hemnes; Karen B Maynard; Hunter C Champion; Linda Gleaves; Niki Penner; James West; John H Newman Journal: Pulm Circ Date: 2012-07 Impact factor: 3.017
Authors: Xinping Chen; Eric D Austin; Megha Talati; Joshua P Fessel; Eric H Farber-Eger; Evan L Brittain; Anna R Hemnes; James E Loyd; James West Journal: Eur Respir J Date: 2017-08-03 Impact factor: 16.671
Authors: Steven M Kawut; Diane Pinder; Nadine Al-Naamani; Amber McCormick; Harold I Palevsky; Jason Fritz; K Akaya Smith; Jeremy A Mazurek; Margaret F Doyle; Margaret R MacLean; Angela DeMichele; David A Mankoff Journal: Ann Am Thorac Soc Date: 2019-11
Authors: Grayson L Baird; Thomas Walsh; Jason Aliotta; Melissa Allahua; Ruth Andrew; Ghada Bourjeily; Alexander S Brodsky; Nina Denver; Mark Dooner; Elizabeth O Harrington; James R Klinger; Margaret R MacLean; Christopher J Mullin; Mandy Pereira; Athena Poppas; Mary Whittenhall; Corey E Ventetuolo Journal: Ann Am Thorac Soc Date: 2021-02